To determine the relative contribution of age and absorption on phenytoin (PHT) kinetics in full-term newborns, we measured PHT apparent half-life (tSoX) 15 times in 9 infants aged 2 to 36 days. PHT was given i.v. 9 times and p.0. 6 times. The PHT t 5~~ ranged from 140 hours in a 2 day old to 3.78 hours in a 36 day old. Whereas the t correlated directly with initial concentration (Ci) in t30eX8 patients )9 days old (r=0.755, p<.05), there was no correlation in 7 younger patients. TS0% varied inversely with age, averaging 84.7 hr (SD 42.6) in patients less than 8 days old and 14.7 hr (SD 7.74) in older patients (t-4.59, p<.01).
Thus, the relation between Ci and tSoz of PHT changes rapidly during the first month of life, a change which must be considered when studying PHT administration and absorption in newborns. For an individual newborn these kinetic changes are unpredictable and repeated PHT measurements are essential.
RISK: BENEFIT CONSIDERATIONS FOR THE SAFE USE OF ISOXSUPRINE IN THE TREATMENT OF PREMATURE LABOR Jane E
Pediatrics, Durham, NC.
Seventy consecutive patients treated w i t h isoxsuprine f o r premature labor were studied t o determine pregnancy factors associated w i t h t o c o l y t i c success, the extent o f placental drug transfer, and time course o f therapy i n order t o define cond i t i o n s which would maximize success and minimize acute neonatal isoxsuprine t o x i c i t y . I n patients w i t h i n t a c t membranes, successful prolongation o f pregnancy >7 days occurred i n 77% o f women w i t h (50% cervical effacement and (3 cm d i l a t a t i o n a t the i n i t i a t i o n of therapy, and i n none w i t h >50% effacement and >3 cm d i l a t a t i o n . Cervical effacement was the primary f a c t o r i n determining success. Cord isoxsuprine concentrations averaged 90% o f maternal concentrations a t delivery. Maternal and cord isoxsuprine concentrations a t d e l i v e r y were inversely correlated w i t h the drug-free i n t e r v a l before delivery. An i n t e r v a l >5 hours was necessary t o a t t a i n a cord concentration o f <2 ng/ml, a level not associated w i t h neonatal problems. Drug-free i n t e rvals (2 hours usually resulted i n cord isoxsuprine values >10 ng/ml , l e v e l s associated w i t h severe neonatal problems. Since 17 o f the 22 infants w i t h cord isoxsuprine concentrations >2 ng/ml and e i g h t o f nine w i t h values >10 ng/ml were delivered o f mothers w i t h >3 cm d i l a t a t i o n o r >50% effacement a t the i ni t i a t i o n o r r e i n s t i t u t i o n of intravenous therapy, most severe neonatal drug-1 eve1 r e l a t e d problems are preventable. 1)the r a t e o f t r a n s f e r o f M across the placenta; 2)the degree t h a t the fetus i s responsible f o r i t s own e l i m i n a t i o n o f M; 3)the selective d i r e c t i o n a l clearance o f M across the placenta. W e placed chronic catheters i n the descending aorta and i n f e r i o r vena cava (IVC) o f s i x pregnant ewes and t h e i r fetuses, and i n t o the u t e r i n e (UTV) and umbilical (UMV) veins. Electromagnetic f l o w transducers were placed around the common u t e r i n e (UTA) and umbilical (UMA) a r t e r i e s . Mwas infused i n t o thematernal IVC a t 15.8mgIhr u n t i l steady s t a t e conditions were achieved. UTA, UTV, UMA, UMV M concentrations and UTA and UMA blood flows were measured a t 5 and 6 hours. The next day, M was infused i n t o the f e t a l IVC a t 3.28 mg/hr and the same procedure followed. RESULTS: Maternal Infusion-The r a t e o f i n t r i n s i c loss o f M by the mother was 15.73 mg/hr o r 99.6% o f the i n f u s i o n rete. The r a t e o f loss o f M from themother t o the fetus was 0.06mg/hr o r 0.4% o f the i n f u s i o n rate. Fetal Infusion-The r a t e o f i n t r i n s i c loss o f M by the fetus was 2.44 mg/hr o r 74.4% o f the i n f u s i o n rate. The r a t e o f loss o f M from the fetus t o themotherwas 0.84mgIhr o r 25.6% o f the i n f u s i o n rate. There was no s i g n i f i c a n t difference between maternal t o f e t a l (1386 ml/hr) and f e t a l t o maternal (984 ml/hr) clearances o f M. Thus, 1)the r a t e o f M t r a n s f e r from themother t o the fetus i s low r e l a t i v e t o the i n f u s i o n r a t e and the fetus i s not a s i g n i f i c a n t route o f e l i m i n a t i o n o f M by the mother; 2)the fetus i s p r i m a r i l y responsible f o r elimi n a t i o n o f M entering i t ' s c i r c u l a t i o n ; and 3)there is no selective clearance o f M across the lacenta i n e i t h e r d i r e c t i o n .
USE OF TRANSCUTANEOUS PC02 ELECTRODES FOR DIAGNOSIS
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Supported by NI R grants DA02280 and GM26691 The v e n t r i c u l a r septum has increased numbers o f i n s u l i n receptors. Isoxsuprine (ISX) has been reported t o cause increased cord blood i n s u l i n . To demonstrate whether an association between ISX exposure, hyperinsulemia and ASH occurred Echocardiography (EC) was performed on 30 i n f a n t s who had ISX exposure and 25 control infants. Normal septal thickness i s 3-4 mm. The control septal thickness was .38+.04. The ISX septal thickness was .55+.13. These are s i g n i f i c a n t l y d i f f e r e n t a t ~4 . 0 0 5 .
-
The ISX treated i n f a n t s were larger, had t h i c k e r v e n t r i c u l a r septae and had higher cord i n s u l i n l e v e l s than non o r p a r t i a l l y treated controls. ISX as a t o c o l y t i c agent may have a s i m i l a r e f f e c t on the fetus as maternal diabetes.
I N UTERO ISOXSUPRINE EXPOSURE: ANATOMIC AND BIO:
322 CHEMICAL CHANGES IN NEONATAL RATS. Carol n Crawford, Ste hanie Bo s, and Christo her ~e& Alfred Bongi *Pa.
Sch. o f ME^. , Pa. Hosp., Dept of Peds., Phila., Pa. Isoxsuprine (ISX) treatment o f prematurelabor. has been associated w i t h diverse metabolic side e f f e c t s including hypoglycemia. This study was designed t o i d e n t i f y anatomic and biochemical changes associated w i t h ISX exposure during pregnancy. 6 timed-pregnant r a t s received ISX a t 2mg/Kg/day a t 120, 96, 72, The data confirm a s i g n i f i c a n t effect o f prenatal ISX on t o t a l BW, CV drugs are less e f f e c t i v e i n reducin the differences, suggesl i v e r glycogen, heart/BW, 1 iver/BW and organ weights of heart, t i n g i t i n t e r f e r s w i t h t h e i r action. 47 T and B narrow the d l f fkidney and lung and suggest t h a t decreased hepatic glycogen may erences, i n d i cating improved t i s s u e perfusion. We conclude the _ be a factor i n neonatal hypoglycemia. PtcCD2 electrode can be valuable as an i n d i c a t o r o f tissue perfUsion i n the care o f i n f a n t s w i t h cardiovascular a l t e r a t i o n s .
*=N **=P< 0.005
